We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CytoSorbents Corporation | NASDAQ:CTSO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.004 | 0.50% | 0.81 | 0.7902 | 0.832 | 0.8356 | 0.7899 | 0.82 | 136,906 | 21:30:21 |
MONMOUTH JUNCTION, N.J., Sept. 18, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using its CytoSorb® blood purification technology to treat life-threatening inflammatory conditions such as sepsis, is a proud sponsor of:
In addition, CytoSorbents' partners have also been active.
Sepsis is a medical emergency that results from of an overzealous immune response to a serious infection, driven by a "cytokine storm," leading to widespread deadly inflammation that can cause multiple organ failure, immune paralysis, and death. According to the Global Sepsis Alliance, sepsis afflicts 20-30 million people each year worldwide, and kills someone every few seconds, despite the use of antibiotics.
Dr. Phillip Chan, MD, PhD, CEO of CytoSorbents stated, "The impact of sepsis to human life is staggering and the problem continues to worsen. We hope to change this trend with our CytoSorb® therapy. While antibiotics work to control the infection, CytoSorb® works to control the excessive inflammatory response through cytokine reduction, removal of bacterial toxins, and redirection of activated white blood cells to the area of infection and away from healthy organs. In doing so, the goal is to prevent or treat organ failure, the leading cause of death in sepsis. We are pleased to support the efforts of these organizations in the fight against this common foe."
About the Global Sepsis Alliance
The Global Sepsis Alliance (GSA) is a non-profit organization supporting the efforts of over 1 million caregivers in more than 70 countries as they seek to better understand and combat what many experts believe to be the leading cause of death worldwide: sepsis. The GSA has rallied the Global Sepsis Community to elevate public, philanthropic and governmental awareness, understanding and support of sepsis and to accelerate collaboration among researchers, clinicians, associated working groups and those dedicated to supporting them.
About the German Sepsis Society
The German Sepsis Society (GSS) is the primary medical society in Germany whose mission is to educate and increase public and professional awareness about sepsis. The organization brings together leaders in sepsis research, diagnostics, treatment, and education in order to also encourage new research, recognize valuable scientific contributions, and foster collaborations to help save lives. A major goal is to support the rapid implementation of effective sepsis diagnostics and therapies into the standard of care treatment for sepsis. Members of the GSS have been heavily involved with SepNet, or the Sepsis Competence Network, a consortium of hospitals and investigators funded for 10 years by the German Federal Ministry of Education to conduct research and clinical trials in sepsis. The GSS also initiated the foundation of the organization, German Sepsis Aid, by people who survived sepsis and their relatives, to provide assistance, information, and networking for those whose lives have been touched by sepsis. For more information, visit www.sepsis-gesellschaft.de/DSG/Englisch
About the Sepsis Alliance™ and Sepsis Heroes Evening
The Sepsis Alliance is a charitable organization run by a team of dedicated laypeople and professionals who share a strong commitment to battling sepsis. The goal is to raise awareness of sepsis through information and educational material so it can be detected and treated early enough that no harm is done. The Sepsis Heroes Evening is an award reception, being held in New York City, designed to raise awareness of sepsis and to recognize the unique contributions of individuals who have committed their time and energy for the cause. This year, Sepsis Alliance honors two organizations, Every Mother Counts and Intermountain Healthcare, and three individuals, Jeff and Helene Zehnder and Laura Messineo, for their contributions to increasing sepsis awareness and improving treatment response. For more information, visit www.sepsisalliance.org
About World Sepsis Day
World Sepsis Day is an initiative of the Global Sepsis Alliance (GSA) and its founding non-profit members: The World Federation of Societies of Intensive and Critical Care Medicine, the World Federation of Pediatric Intensive and Critical Care Societies, the World Federation of Critical Care Nurses, the International Sepsis Forum, and the Sepsis Alliance. The goals of World Sepsis Day are to:
For more information, visit www.world-sepsis-day.org
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.
Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
SOURCE CytoSorbents Corporation
Copyright 2014 PR Newswire
1 Year CytoSorbents Chart |
1 Month CytoSorbents Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions